Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

- -

Issuance of convertible royalty participation units - 7,737

Proceeds on exercise of stock options - 1

Proceeds on exercise of warrants 36 17

Repayment of capital lease obligation - (5)

-------------------------------------------------------------------------

Cash provided by financing activities $ 36 $ 7,750

-------------------------------------------------------------------------

Funds from (purchases of) short-term investments 6,880 (1,364)

Proceeds on disposal equipment 12 -

Purchases of equipment (75) (72)

-------------------------------------------------------------------------

Cash provided by (used in) investing activities $ 6,817 $ (1,436)

-------------------------------------------------------------------------

Increase in cash and cash equivalents $ 4,431 $ 3,206

Cash and cash equivalents, beginning of period 2,945 5,743

-------------------------------------------------------------------------

Cash and cash equivalents, end of period $ 7,376 $ 8,949

-------------------------------------------------------------------------

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase II and preclinical), the prevention of catheter-related infections (Phase III) and the treatment of dermatological diseases (Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, C
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Controlled Substance ... Alliance, which helps companies check the legal requirements around ... expand to China. , As their international operations ... globally adopting software solutions built as a result of ...
(Date:1/22/2015)... , Nueva Jersey , 22 de enero ... for Biomedical Research abre hoy su llamada a nominaciones ... cuya investigación científica ha hecho, o tiene el potencial ... salud humana. Las nominaciones se aceptarán hasta el 15 ...
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... the consolidating pharmaceutical industry began. For those of you who ... were talking about the hostile bid by French pharmaceutical giant ... Aventis . , ,This would create a real major ... would create the worlds third-largest pharmaceutical company after No. 1 ...
... response, it looks as if Small Tree Communications ... group of former Cray and SGI employees to brave the ... Grove Heights, Minn.-based business, with ties to legacy Chippewa Valley ... breakthrough product for Apple Computers enterprise customers who need enhanced ...
... Madison, Wis., -- Broadjam Inc. , a Madison-based provider ... publishers, has been selected to create and implement a ground-breaking ... . , ,In an intriguing move from an industry often ... onto the Internet in time for its annual awards show ...
Cached Biology Technology:The Industry Impact of Two Big Pharmas Mating 2The Industry Impact of Two Big Pharmas Mating 3The Industry Impact of Two Big Pharmas Mating 4The Industry Impact of Two Big Pharmas Mating 5The Industry Impact of Two Big Pharmas Mating 6The Industry Impact of Two Big Pharmas Mating 7Former SGI/Cray Team Develops Products for G5 Platform 2Former SGI/Cray Team Develops Products for G5 Platform 3
(Date:1/22/2015)... 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), the ... campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz will ... capacity to meet customer demand. Logo ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by Dr. ...
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... Infinisource has launched its new NXG series of time clocks ... a higher standard for collecting attendance and labor data and ... installation, touch screen interface and seamless connection to cloud-based iSolved, ... solution for the small to mid-size employer. The ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Infinisource's NXG series sets new time clock standard 2
... KNOXVILLE -- Research by a small group of microbiologists ... of the Earth: the realm just beneath the deep ocean ... on our planet. Beth Orcutt, a post-doctoral fellow at ... presented her new findings about this little researched realm today ...
... research studies should not be disclosed to participants without ... of the European Society of Human Genetics today (Monday). ... Policy, Management and Evaluation at the University of Toronto, ... held by many ethicists that individual genetic research findings ...
... Researchers at Rice University, Purdue University and the ... about why some fluids containing polymers -- including saliva ... do not. The findings are published online this ... Study co-author Matteo Pasquali, professor in chemical and biomolecular ...
Cached Biology News:New research into the deep ocean floor yields promising results for microbiologists 2Should the results of individual genetic studies be disclosed to participants? 2Should the results of individual genetic studies be disclosed to participants? 3Answer to saliva mystery has practical impact 2
... A thermostable, thermoactive designer enzyme ... single-tube-reaction. AccuRT RNA PCR enzyme allows ... be performed at elevated temperatures (65C), ... from the template and results in ...
HLA-DRbeta (DA2)...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
... polyclonal NPY Y2 Receptor antiserum This ... the spinal level and is currently being characerized ... both rat and mouse and appears to work ... seen in rat. For full characterizarion in dorsal ...
Biology Products: